Data on synthesis of methylene bisphosphonates and screening of their inhibitory activity towards HIV reverse transcriptase  by Yanvarev, D.V. et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 8 (2016) 1157–1167http://d
2352-34
(http://c
DOI
n Corr
E-m
1 Thjournal homepage: www.elsevier.com/locate/dibData ArticleData on synthesis of methylene bisphosphonates
and screening of their inhibitory activity towards
HIV reverse transcriptase
D.V. Yanvarev a,n,1, A.N. Korovina a,1, N.N. Usanov a,
O.A. Khomich a, J. Vepsäläinen b, E. Puljula b, M.K. Kukhanova a,
S.N. Kochetkov a
a Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova st.32, Moscow, Russia
b School of Pharmacy, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finlanda r t i c l e i n f o
Article history:
Received 10 June 2016
Received in revised form
29 June 2016
Accepted 19 July 2016
Available online 26 July 2016x.doi.org/10.1016/j.dib.2016.07.039
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author.
ail address: JDmitry@hotmail.com (D.V. Yan
ese authors contributed equally to this woa b s t r a c t
Inorganic pyrophosphate (PPi) mimetics designed on a basis of
methylenediphosphonic acid backbone are promising inhibitors
of two key HIV replication enzymes, IN [1] and RT [2]. Herein,
we present chemical synthesis of eleven methylenebispho-
sphonates (BPs) with their NMR and HRMS analysis synthesized
via ﬁve different ways. Also, we present data on inhibition of
HIV RT catalyzed phosphorolysis and polymerization by syn-
thesized BPs using two methods based on denaturing urea PAGE.
Tests were also performed for thymidine analogue mutations
reverse transcriptase (TAM RT), which was expressed and pur-
iﬁed for that. Structure–activity relationships and inhibitory
activity data of synthesized BPs are presented in “Methylene
bisphosphonates as the inhibitors of HIV RT phosphorolytic
activity” [2].
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Dubject area Chemistry, Biochemistry
ore speciﬁc sub-
ject areaChemical synthesis, puriﬁcation, NMR and HRMS data, protein expression
and puriﬁcation, PAGE analysisype of data Table, image, ﬁgure
ow data was
acquired High-resolution electrospray mass spectra were obtained on Applied Bio-
systems/MDS Sciex QSTAR XL (USA);
 NMR spectra were recorded on 400 MHz (1H), 182 MHz (31P), and 92 MHz
(13C) AMX III 400 Bruker spectrometer (USA);
 All oligonucleotides were synthesized on an automatic ABI 3400 DNA syn-
thesizer (Applied Biosystems, USA);
 Radioactive products were detected using Typhoon FLA 9500 biomolecular
imager “GE Healthcare” (UK)
 pH measurements were performed using FEP30 Mettler Toledo (Switzer-
land) pH-meter with LE409-electrode.ata format Filtered and analyzed
xperimental
factorsStarting compounds were either purchased or synthesized using already
published synthetic protocols. The plasmid encoding TAM RT was a kind gift
from Professor S.F.J. Le Grice.xperimental
featuresCompounds were synthesized and their structure was identiﬁed by 1H, 31P,
13C and 19F NMR and conﬁrmed by high resolution mass spectrometry.
Compounds synthesized either here or earlier were tested as inhibitors of
HIV RT catalyzed reactions.ata source
locationEngelhardt Institute of Molecular Biology, 32 Vavilov St., Moscow, Russiaata accessibility The data is included in this article.D
Value of the data The article describes the synthesis and physicochemical characterization of eleven new methyle-
nebisphosphonates for biochemical research.
 The data possessed (validated) suppression of HIV RT catalyzed reactions by new methylenebi-
sphosphonates in vitro and can be used for further design of HIV replication inhibitors.
 The data on inhibition of RT-pyrophosphorolysis and DNA-polymerization allow to deepen
understanding of how HIV RT interacts with small molecule competitive inhibitors.1. Data
The data presented here describe synthesis and physicochemical characterization of methylene-
bisphosphonates (BPs) of the following ﬁve different types: substituted hydroxymethylene BPs, α-
aminomethylene BPs, β-aminomethylene BPs, α-alcoxymethylene BPs, and bis-alkylated BPs. We also
present protocols for HIV reverse transcriptase puriﬁcation and screening of synthesized BPs as its
inhibitors in vitro and PAGE analysis of RT-catalyzed reactions.2. Experimental design, materials and methods
All reagents were purchased from Acros Organics or Aldrich and used without drying or pur-
iﬁcation. Column chromatography was performed on Kieselgel (40–63 μm, Merck, Germany). TLC was
carried out on Kieselgel 60 F254 precoated plates (Merck, Germany).
D.V. Yanvarev et al. / Data in Brief 8 (2016) 1157–1167 1159The inhibitor concentrations were measured by UV absorption according to molar extinction
coefﬁcients and compared with 1H NMR using the known concentrations of D1-tert-butanol in D2O.
All pH measurements were conducted on FEP-30 Mettler Toledo pH-meter (Switzerland).
High-resolution mass spectra (HRMS) were registered in a positive ion mode on a Bruker Daltonics
micrOTOF-Q II instrument using electrospray ionization (ESI). Interface capillary voltage: 4500 V;
mass range from m/z 50 to 3000; external calibration (Electrospray Calibrant Solution, Fluka);
nebulizer pressure: 0.4 bar; ﬂow rate: 3 mL/min; dry gas: nitrogen (4 L/min); interface temperature:
200 °C.
NMR spectra were recorded on 400 MHz (1H), 182 MHz (31P), and 92 MHz (13C) AMX III 400
Bruker spectrometer. Chemical shifts are reported in parts per million (ppm) using tetramethylsilane
(1H), tert-butanol-d1 (13C), and 85% H3PO4 (31P) as external standards. 13C and 31P NMR spectra were
proton-decoupled unless otherwise speciﬁed.
Radioactive triphosphate [γ-32P]-ATP (molar activity 6000 Ci/mM) was a kind gift from Dr. Yu. S.
Skoblov. HIV-1 RTwt (21,500 U/ml) was purchased from “CalBioChem” (USA). Thermostable inorganic
pyrophosphatase and T4 polynucleotide kinase were purchased from “New England BioLabs” (USA).
All oligonucleotides were synthesized by the phosphoramidite method on an automatic ABI 3400
DNA synthesizer (Applied Biosystems, USA) under conditions recommended by manufacturer and
puriﬁed by electrophoresis in a 20% polyacrylamide/7 M urea gel.
2.1. Chemistry
Bisphosphonates were prepared according to the following methods: (3), (7–9) (method A), (1),
(2), (4) (method B), (10) by the method C, (5) D, (6) E and (11) F. For 1H, 13C, 31P, 14N, 15N NMR spectra
images see Supplementry document Figs. 1,2.
The bisphosphonates synthesized by Method A (3,7–9).
.The acyl chlorides were prepared by 4–6 h reﬂuxing of 5–7 g of the corresponding acid with
2 equivalents of thyonylchloride and 50 mL dimethylformamide in 8–15 mL of dry dichloromethane.
After all volatile solvents were removed by vacuum evaporation then vacuum distillation at 0.8–
1.5 mm Hg was applied (0.1 mm Hg in case of 9) to give 75–80% of the target compounds as we
described earlier [1].
After distillation acyl chlorides (3 mmol) were solved under Ar in dry benzene (10 mL) and was
added dropwise on ice bath to a solution of 3 mmol triethylphosphite in dry benzene (10 mL) under
vigorous stirring. Stirring was continued for additional 2–3 h at 5 °C then mixture of 3 mmol of
diethylphosphite and 0.3 mmol diisopropylamine was added and stirring was continued for 4–5 h at
5 °C. All volatile component of reaction mixture were removed by vacuum evaporation and tetrae-
sters 3, 8, 9 were puriﬁed by silica gel column chromatography with CHCl3–MeOH (0–15% MeOH) as
an eluent. Solvents were removed in vacuo the residue was solved in dry chloroform and ethyl groups
were routinely removed using 5 equivalents of TMSBr overnight at room temperature followed by
methanolysis for 2 h.
2.1.1. 1-Hydroxy-2-(3,4-diﬂuorophenyl)-ethylidene-1,1-bisphosphonate (3)
After methanolysis solvents were removed in vacuo, the residue was dissolved in 3 ml of water
then 1М NaOH was added until pH 7 was reached. Solution was lyophilized to give 850 mg of (3)
(2Naþ) as white powder (yield 78% according to acyl chloride).
Fig. 2. Bisphosphonates synthesized previously and studied as HIV RT inhibitors.
Fig. 1. The bisphosphonates synthesized for this publication.
D.V. Yanvarev et al. / Data in Brief 8 (2016) 1157–116711601H NMR (400 MHz; D2O, pH 1): δ¼7.31 (m, J¼12.2 Hz, J¼8.1 Hz, J¼1.9 Hz), 7.12 (m), 3.17 (t,
J¼12.6 Hz).
13C{1H} NMR (101 MHz; D2O, pH 1): δ¼152.86 (dd, J1¼52.0 Hz, J2¼12.6), 150.93 (dd, J1¼52.0 Hz,
J2¼12.6), 138.17 (broad s), 130.42 (d, J¼3.0 Hz), 122.76 (d, J¼16.6 Hz), 119.02 (d, J¼16.6 Hz), 77.0 (t,
J¼128.2 Hz), 41.3 (s).
31Р{1H} NMR (162 MHz; D2O, pH 1): δ¼18.65 (s).
19F NMR (471 MHz, D2O, pH 1) δ 139.01 (d, J¼21.7 Hz, 1F), 140.90 (d, J¼21.6 Hz, 1F).
HREIMS: calculated for C8H10F2O7P2 [МþH]þ 317.9870; found: 317.9867.2.1.2. 1-Hydroxy-1-phenylmethylidene-1,1-bisphosphonate (7)
After methanolysis solvents were removed in vacuo, the residue was dissolved in 5 ml of water
then 1М KOH was added until pH 5 was reached. Clear solution was lyophilized to give 938 mg of
(7)(2 Kþ) as white powder (yield 91% according to acyl chloride).
1H NMR (400 MHz; D2O, pH 5): δ¼7.69 (d, JHH¼7.3 Hz, 2 H, Ph), 7.40 (dd, JHH¼7.3 Hz, 2H, Ph), 7.36
(d, JHH¼7.3 Hz, 1H, p-Ph).
13C{1H} NMR (101 MHz; D2O, pH 5): δ¼140.09 (s), 131.41 (s), 131.07 (s), 129.42 (s), 78.86 (t, J1PC ¼
145.2 Hz, PCP).
31Р{1H} NMR (162 MHz; D2O, pH 5): δ¼16.02 (s).
HREIMS: calculated for C7H10O7P2 [МþH]þ 267.9902; found: 267.9897.
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After methanolysis solvents were removed in vacuo, the residue was suspended in 6 ml of water
then 1М KOH was added until pH 9 was reached. Clear solution was lyophilized to give 760 mg of
(8)(3 Kþ) as white powder (yield 61% according to acyl chloride).
1H NMR (400 MHz; D2O, pH 9): δ¼d 7.35-7.20 (m, Ph, 5H), 2.63 (t, J¼7.1 Hz, CH2–PCP, 2H), 2.08–
1.96 (m, CH2–PCP, 2H), 1.66–1.57 (m, –(CH2)3–, 6H).
31Р{1H} NMR (162 MHz; D2O, pH 9): δ¼18.5 (s).
13C{1H} NMR (101 MHz; D2O, pH 9, t-BuOD 30.3 ppm): δ¼144.4 (s), 129.6 (s), 126.8 (s), 74.1 t
(JPC¼147 Hz), 35.2 (s), 33.9 (s), 32.0 (s), 30.1 (s), 29.9 (s).
HREIMS: calculated for C12H20O7P2 [МþH]þ 338.0684; found: 338.0680.
2.1.4. 1-Hydroxy-3-(3,4,5-trimethoxyphenyl)-propylidene-1,1-bisphosphonate (9)
After methanolysis solvents were removed in vacuo, the residue was dissolved in 5 ml of water
then 1М NaOH was added until pH 6 was reached. Solution was lyophilized to give 825 mg of (9)
(2Naþ) as white powder (yield 64% according to acyl chloride).
1H NMR (400 MHz; D2O, pH 6): δ¼6.72 (s, m-Ph, 2H), 3.83 (s, m-OCH3, 6H), 3.71 (s, p-OCH3, 3H),
2.88–2.82 (m, 2H, CH2–Ph), 2.25–2.10 (m, 2H, CH2–PCP).
31Р{1H} NMR (162 MHz; D2O, pH 6): δ¼18.83 (s).
13C{1H} NMR (101 MHz; D2O, pH 6, t-BuOD 30.3 ppm): δ¼155.07 (s,m-Ph), 142.97 (s, p-Ph), 137.44
(s, ipso-Ph), 108.79 (s, o-Ph), 76.74 (t, JPC¼134.0 Hz, P-C-P), 63.61 (s, p-OCH3), 58.84 (s, m-OCH3).
HREIMS: calculated for C12H20O10P2 [МþH]þ 386.0532; found: 386.0535.
The bisphosphonates synthesized by Method B (1, 2, 4).
.2.1.5. Tetraethyl diazomethylenediphosphonate
The suspension of t-BuOK (2.68 g, 24 mmol) in toluene (15 mL) was cooled using an ice bath (0–
5 °С). A solution of tetraethyl methylenediphosphonate (5.76 g, 20 mmol) in toluene (15 mL) was
added dropwise to the reaction ﬂask. Resulting viscous mixture was stirred for 20 min, where upon a
solution of p-toluenesulfonyl azide (4.33 g, 22 mmol) in toluene (20 mL) was added dropwise while
the temperature was kept below 5 °С. The mixture turned intensely yellow and a pale yellow solid
began to precipitate. The ice bath was removed and stirring was continued for 3 h at 25 °С. The solid
was separated by centrifugation; solvent was evaporated under reduced pressure. The residue was
chromatographed on a silica gel column (benzene-ethyl acetate, 2:1) to afford 1.9 g (30%) of the
desired product as yellow oil.
1H NMR (400 MHz, CDCl3): δ¼1.34 (t, 3JН–Н¼7.0 Hz, 12Н, СН3СН2О), 4.16 (m, 8Н, СН3СН2О).
13C{1H} NMR (101 MHz; CDCl3): δ¼16.2 (t, 3JС–Р ¼ 3.4 Hz, СН3СН2О), 38.8 (t, 1JС–Р ¼ 204.1 Hz,
Р–СN2–Р), 63.4 (t, 2JС–Р ¼ 2.7 Hz, СН3СН2О).
31Р{1H} NMR (162 MHz; CDCl3): δ¼11.9 (s).
15N{1H} inverse gated NMR (40.6 MHz; CDCl3): δ¼127.6 (t, 3JN–Р¼3.6 Hz, С¼Nþ¼N-), 28.0
(s, С¼Nþ¼N).
HREIMS: calculated for С9Н20N2О6P2 [МþH]þ 315.0869; found: 315.0873.
2.1.6. General procedure for tetraethyl alkoxymethylenediphosphonate
To a solution of tetraethyl diazomethylenediphosphonate (0.5 g, 1.6 mmol) and alcohol (4.8 mmol)
in 15 mL of anhydrous toluene Cu(OTf)2 (5.8 mg, 0.016 mmol) was added. The mixture was heated
under reﬂux for 16 h. Solvent was evaporated under reduced pressure; the residue was chromato-
graphed on a silica gel column, eluted with a CH2Cl2–MeOH (0–3% MeOH) to afford the desired
product.
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Н¼7.1 Hz, 4JН–Р¼4.7 Hz, 12Н, СН3СН2О), 3.96 (t, 2JН–Р¼17.2 Hz, 1Н, Р–СН(OBn)–Р), 4.11 (m, 8Н,
СН3СН2О), 4.73 (s, 1Н, OCH2Ph), 7.23 (m, 5Н, Ph). 13C{1H} NMR (101 MHz; CDCl3): δ¼16.2 (d, 3JС–
Р¼2.2 Hz, СН3СН2О), 63.1 (m, СН3СН2О), 71.6 (t, 1JС–Р¼156.5 Hz, Р–СН(OBn)–Р), 75.5 (t, 3JС–
Р¼5.0 Hz, OCH2Ph), 136.3 (Ph). 31Р{1H} NMR (162 MHz; CDCl3): δ¼16.1 (s).
HREIMS: calculated for С16Н28О7P2 [МþNa]þ 417.1202; found: 417.1191.
2.1.6.2. Tetraethyl 3,4-dichlorobenzyloxymethylenediphosphonate. 1H NMR (400 MHz; CDCl3): δ¼1.33
(td, 3JН–Н¼7.1 Hz, 4JН–Р¼2.8 Hz, 12Н, СН3СН2О), 4.00 (t, 2JН–Р¼17.2 Hz, 1Н, Р–СН(OAr)–Р), 4.21
(m, 8Н, СН3СН2О), 4.78 (s, 1Н, OCH2Ar), 7.21 (dd, 3JН–Н¼8.2 Hz, 4JН–Н¼1.9 Hz, 1H, o-Ar), 7.39 (d,
3JН–Н¼8.2 Hz, 1H, m-Ar), 7.49 (d, 4JН–Н¼1.9 Hz, 1H, o-Ar). 13C{1H} NMR (101 MHz; CDCl3): δ¼16.6
(СН3СН2О), 63.5 (СН3СН2О), 72.5 (t, 1JС–Р¼157.0 Hz, Р–СН(OAr)–Р), 74.5 (t, 3JС–Р¼5.2 Hz,
OCH2Ar), 127.7, 130.4, 130.5, 132.3, 132.7, 137.1. 31Р{1H} NMR (162 MHz; CDCl3): δ¼14.3 (s).
HREIMS: calculated for C16H26O7P2Cl2 [МþН]þ¼463.0609; found 463.0613.
2.1.6.3. Tetraethyl 3,4-dichlorophenethoxymethylenediphosphonate. 1H NMR (400 MHz; CDCl3): δ¼1.29
(dt, 4JН–Р¼8.6 Hz, 3JН–Н¼7.1 Hz, 12Н,СН3СН2О), 2.86 (t, 3JН–Н¼6.4 Hz, 2H, ArCH2CH2), 3.88 (t, 2JН–
Р¼17.5 Hz, 1Н, Р–СН(OR)–Р), 3.96 (t, 3JН–Н¼6.4 Hz, 2H, ArCH2CH2), 4.12 (m, 8Н, СН3СН2О), 7.07
(dd, 3JН–Н¼8.2 Hz, 4JН–Н¼2.1 Hz, 1H, o-Ar), 7.31 (d, 3JН–Н¼8.2 Hz, 1H, m-Ar), 7.35 (d, 4JН–Н¼2.1 Hz,
1H, o-Ar). 13C{1H} NMR (101 MHz; CDCl3): δ¼16.5 (СН3СН2О), 35.5 (ArCH2CH2), 63.4 (СН3СН2О),
73.7 (t, 1JС–Р¼157.2 Hz, Р–СН(OR)–Р), 74.6 (t, 3JС–Р¼4.7 Hz, ArCH2CH2), 128.6, 130.2, 130.4, 131.1,
132.2, 139.0. 31Р{1H} NMR (162 MHz; CDCl3): δ¼14.1 (s).
HREIMS: calculated for C17H28O7P2Cl2 [МþН]þ¼477.0765; found 477.0771.
2.1.7. General procedure for alkoxymethylenediphosphonic acids
The mixture of tetraethyl alkoxymethylenediphosphonate (20 mg) and TMSCl (0.2 mL) was placed
in a sealed tube and heated at 120 °С for 8 h. TMSCl was evaporated under reduced pressure; the
residue was quenched with aq. MeOH. Solvent was evaporated under reduced pressure; product was
obtained with quantitative yield.
2.1.7.1. 3,4-dichlorobenzyloxymethylenediphosphonic acid (1). 1H NMR (400 MHz; D2O): δ¼3.72 (t, 2JН–
Р¼15.8 Hz, 1Н, Р–СН(OAr)–Р), 4.71 (s, 1Н, OCH2Ar), 7.32 (dd, 3JН–Н¼8.3 Hz, 4JН–Н¼1.9 Hz, 1 H, o-
Ar), 7.45 (d, 3JН–Н¼8.3 Hz, 1 H, m-Ar), 7.60 (d, 4JН–Н¼1.9 Hz, 1 H, o-Ar).
13C{1H} NMR (101 MHz; D2O): δ¼74.1 (t, 3JС–Р¼4.8 Hz, OCH2Ar), 75.7 (t, 1JС–Р¼138.7 Hz, Р–СН
(OAr)–Р), 128.5, 130.6, 130.7, 132.4, 132.8, 138.6.
31Р{1H} NMR (162 MHz; D2O): δ¼11.9 (s).
HREIMS: calculated for C8H10Cl2O7P2 [МH] 348.9218; found: 348.9219.
2.1.7.2. 3,4-dichlorophenethoxymethylenediphosphonic acid (2). 1H NMR (400 MHz; D2O): δ¼3.00 (t,
3JН–Н ¼ 7.6 Hz, 2H, ArCH2CH2), 3.67 (t, 2JН–Р ¼ 15.0 Hz, 1Н, Р–СН(OR)–Р), 3.98 (t, 3JН–Н ¼ 7.6 Hz,
2H, ArCH2CH2), 7.33 (dd, 3JН–Н ¼ 8.3 Hz, 4JН–Н¼1.8 Hz, 1H, o-Ar), 7.51 (d, 3JН–Н ¼ 8.3 Hz, 1H, m-Ar),
7.58 (d, 4JН–Н ¼ 1.8 Hz, 1H, o-Ar).
13C{1H} NMR (101 MHz; D2O): δ¼35.1 (ArCH2CH2), 73.9 (t, 3JС–Р¼4.3 Hz, ArCH2CH2), 77.5 (t, 1JС–
Р¼130.6 Hz, Р–СН(OR)–Р), 129.3, 129.6, 130.6, 131.2, 131.7, 139.9.
31Р{1H} NMR (162 MHz; D2O): δ¼12.7 (s).
HREIMS: calculated for C9H12Cl2O7P2 [М-H]- 362.9377; found: 362.9374.
2.1.7.3. Benzyloxymethylenediphosphonic acid (4). 1H NMR (400 MHz; D2O): δ¼3.88 (t, 2JН–Р¼15.6 Hz,
1Н, Р–СН(OBn)–Р), 4.87 (s, 1Н, OCH2Ph), 7.55 (m, 5Н, Ph).
13C{1H} NMR (101 MHz; D2O): δ¼75.4 (t, 3JС–Р¼2.0 Hz, OCH2Ph), 76.0 (t, 1JС–Р¼134.7 Hz, Р–СН
(OBn)–Р), 128.50 (s), 128.9 (s), 129.1 (s) 138.3 (s).
31Р{1H} NMR (162 MHz; D2O): δ¼12.3 (s).
HREIMS: calculated for C8H12O7P2 [МH] 282.0058; found: 295.0023.
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.2.1.8. Vinylidenediphosphonic acid (VDPA)
VDPA was prepared by thermal dehydration of tetrasodium salt of etidronic acid followed by
partial deionization of tetrasodium VDPA by CO2 gas [3]. The thermal conditions and dehydration
time were optimized (350 °C, 5 h) to get 97–100% conversion of etidronate. Reaction was monitored
by 31P NMR analysis, which revealed VDPA and PPi to be the main reaction products (490%).
Tetrasodium etidronate was heated 5 h at 350 °C in mufﬂe furnace. After the reaction was com-
pleted and cooled to room temperature, the residue was dissolved in a minimal amount of water at
20 °C, and insoluble materials were ﬁltered off. The ﬁltrate was diluted twofold with water and a CO2
ﬂow was passed through at þ5 °C up to pH 6. The solution was left at this temperature for additional
5–6 h and the precipitated NaHCO3 was ﬁltered off. The residue was crystallized from glacial acetic
acid and ﬁnal purity of disodium VDPA was 495%. Crystals were diluted with water and VDPA
concentration measured by 1H-NMR. This solution was used for syntheses presented below.
2.1.8.1. 2-N-benzyl-2-aminoethylidene-1,1-bisphosphonate (10). A solution of disodium VDPA (1 eq) in
5 ml of 95% acetic acid and benzylamine (2 eq) was stirred at 80 °C till homogenous syrup formation.
Then reaction mixture was sealed in a glass tube and heated at 120 °C for 5 h. The reaction mixture
was poured into 50% water/ethanol mixture, acidiﬁed with HCl to pH 1 and allowed to crystallize at
5 °C. The precipitated zwitterionic bisphosphonate was of 495% purity according to 1H, and 31P
NMR data.
1H NMR (400 MHz; D2O, pH 8): δ¼7.39–7.28 (m, 5 H, Ph), 4.32 (s, 2H, Ph–CH2), 3.39 (dt,
J3PH¼15.1 Hz, J2HH¼6.5 Hz, 2H, PCP–CH2), 2.05 (tt, J2PH¼20.0 Hz, J2HH¼6.5 Hz, 1H, PCHP).
13C{1H} NMR (101 MHz; D2O, pH 8): δ¼135.3 (s), 132.1 (s), 131.9 (s), 131.6 (s), 48.9 (s), 37.7 (t,
J1PC¼110.1 Hz).
31Р{1H} NMR (162 MHz; D2O, pH 8): δ¼16.6 (s).
HREIMS: calculated for C9H15NO6P2 [МþH]þ 295.0374; found: 295.0374.
The bisphosphonate synthesized by Method D (5).
.2.1.9. 1,1-dibenzyl-methylene-1,1-bisphosphonic acid (5)
A solution of 1.2 mL (4 mmol) tetraisopropyl methylenebisphosphonate in dry THF (5 mL) stirred
under the Ar atmosphere at 0 °C was added to 400 mg (10 mmol) of NaH (60% suspension in oil) in
dry THF (5 mL). Stirring was continued for 1 h at, and then for 3 h at rt. A solution of 1.27 g (10 mmol)
benzylchloride in THF (5 mL) was added to the resulted carbanion solution and stirred overnight at rt.
The reaction was quenched with saturated NH4Cl (20 mL), extracted with DCM (350 mL), dried
(Na2SO4) and concentrated in vacuo. The target bisphosphonate was puriﬁed as it was previously
reported [3], by column chromatography on silica gel, eluting with EtOAc/MeOH gradient (0-25%
MeOH). The tetraisopropyl ester was reﬂuxed with 48% HBr (4 mL) for 2 h followed by co-evaporation
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viscous oil. Yield 0.96 g as free acid (67% according to tetraisopropyl methylenebisphosphonate).
1H NMR (400 MHz; D2O, pH 5): δ¼7.5 (d, J¼6.7 Hz, 6H), 7.3–7.2 (m, 4H), (t, J¼16.3 Hz, 4H).
13C{1H} NMR (101 MHz; D2O, pH 5): δ¼141.0 (s), 134.5 (s), 130.3 (s), 129.1 (s), 50.1 (t, J¼113.1 Hz),
41.2 (t, J¼3.4 Hz).
31Р{1H} NMR (162 MHz; D2O, pH 5): δ¼22.5 (s).
HREIMS: calculated for C15H18O6P2 [МþH]þ 356.0578; found: 356.0573.
The bisphosphonate synthesized by Method E (6).
.2.1.10. 1-Hydroxy-2-(2-phenylpyridine-1-yl)ethylidene-1,1-bisphosphonic acid (6)
Ethylbromoacetate (6 mmol) was added to a solution of the substituted pyridine (5 mmol) in ether
(15 mL) and the reaction mixture was stirred overnight at rt to give the substituted pyridinium
bromides as white precipitates by the end of reaction. To improve the yield, supernatant was kept for
2 h at 0 °C and the formed crystals were added to ones formed during the course of reaction. The
crystals were suspended in 4 ml of 2 M HCl and reﬂuxed for 2 h, then solvent was removed in vacuo
and the residue was re-evaporated with 5 ml of water. Yield was 495% and purity was 499%
according to 1H-NMR spectrum.
The obtained o-substituted pyridiniumacetic acid (2 mmol) was dissolved in the mixture of
phosphorous acid (2 mmol) and methanesulfonic acid (5 mL) in dry benzene (10 mL) and was
reﬂuxed for 10 min till the mixture became homogenous. The reaction mixture was cooled to 50 °C
and a solution of POCl3 (3 mmol) in dry benzene (10 mL) was added dropwise for 30 min, maintaining
the temperature below 70 °C, then the reaction mixture was stirred with reﬂux for addition 5 h. The
viscous yellowish reaction mixture was cooled to 40 °C and pooled into the ice-cooled 3N HCl
(50 mL) under vigorous stirring and then reﬂuxed for 2 h. The water layer was separated, dried in
vacuo, and re-evaporated with water (28 mL), then dissolved in 3–4 mL of boiling water; pH
changed to 4 by adding 2 M KOH and the solution was kept for 24 h at þ5 °C till the bispho-
sphonate (6) crystallized. Yield 68% as white crystals of dipotassium salt.
1H NMR (400 MHz, D2O. pH 2) δ 9.18 (d, J¼5.6 Hz, 1H), 8.47 (t, J¼7.7 Hz, 1H), 8.04–7.80 (m, 1H),
7.59 (s, 3H), 5.31 – 4.98 (m, 1H).
31Р{1H} NMR (162 MHz, D2O. pH 2) δ 8.83.
13C{1H} NMR (101 MHz; D2O, pH 2): δ 159.90, 148.91, 137.04, 135.12, 132.61, 131.90, 126.80, 76.01 (
t, J¼134.0 Hz).
HREIMS: calculated for C13H16NO7P2 [МþH]þ 360.0402; found: 360.0405.
The bisphosphonate synthesized by Method F (11).
.2.1.11. 1-Amino-2-pyridine-1-yl-ethylidene-1,1-bisphosphonic acid (11)
Bromoacetonitrile (6 mmol) was added to a solution of the pyridine (5 mmol) in ether (15 mL) and
the reaction mixture reﬂuxed for 6 h to give the substituted pyridinium bromides as white
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dried in vacuo. Yield was 496%.
Herein, we optimized the synthesis of 1-amino-BPs published earlier [4] by changing ionic liquid
and temperature conditions. A suspension of nitrile (2 mmol), phosphorous acid (2 mmol) and
methanesulfonic acid (5 mL) in dry benzene (10 mL) was reﬂuxed for 40 min till the mixture became
homogenous. Reaction mixture was cooled to 60–65 °C and a solution of POCl3 (3 mmol) in dry
benzene (10 mL) was added dropwise for 30 min, maintaining the temperature below 70 °C, then the
reaction mixture was stirred with reﬂux for additional 12 h. The viscous yellowish reaction mixture
was cooled to 40 °C and pooled into the ice-cooled 3N HCl (50 mL) under vigorous stirring and then
reﬂuxed for 2 h. The water layer was separated, concentrated in vacuo to a volume of 3 mL and kept
for 24 h at þ5 °C till the bisphosphonate (11) crystallized. Yield 72% as white crystals.
1H NMR (500 MHz, D2O) δ 8.98 (d, J¼6.1 Hz, 2H), 8.62 (t, J¼7.9 Hz, 1H), 8.09 (t, J¼7.2 Hz, 2H), 5.24
(t, J¼9.8 Hz, 2H).
31Р{1H} NMR (202 MHz, D2O) δ 8.83.
13C{1H} NMR (126 MHz, D2O) δ 146.94, 145.99, 127.68, 61.45, 58.04, 57.07, 56.09.
HREIMS: calculated for C7H13N2O6P2 [МþH]þ 283.0243; found: 283.0240.2.2. RT inhibition
2.2.1. [50-32P]-labeled primer–template complex preparation
Synthetic 42-nt oligonucleotide (50-CCA GTT AGC GTA GTC AAG GCT CGA GAC TAC AGG AAT TGA
CGG-30) and 19-nt oligonucleotide (50-CCG TCA ATT CCT GTA GTC T-30) were used to obtain the pri-
mer–template complex. The reaction mixture (30 μl) contained 70 mM Tris–HCl (pH 7.6), 10 mM
MgCl2, 5 mM dithiothreitol, 50 pmol of 19-nt primer, 5U T4 polynucleotide kinase, and 100 μCi of
[γ-32P]rATP. After 1 h of incubation at 37 °C, T4 polynucleotide kinase was inactivated by heating at
65 °C for 20 min. To obtain the primer–template complex, [50-32P]-primer was annealed with a 1.5-
excess 42-nt DNA template by heating at 65 °C for 5 min and cooling to room temperature. This
complex was puriﬁed using an illustra™ microspin G-25 column from “GE Healthcare” (UK).
2.2.2. Expression and puriﬁcation of ТАМ reverse transcriptase enzyme
The plasmid p6HRT encoding His-tagged TAM HIV-1 reverse transcriptase (RT; M41L, D67N, K70R,
T215Y, K219Q) was a kind gift from Professor S.F.J. Le Grice. The expression cassette contained also
HIV-1 protease gene allowing formation of p66/p51 heterodimer. The protein was expressed in
Rosetta (DE3) E. coli strain. TAM RT was puriﬁed using standard Ni-NTA agarose procedure [5] (Lysis
buffer: 25 mM Tris–HCl, 350 mM NaCl, 5 mM β-mercaptoethanol, 0,1% Triton X-100, 10% glycerol,
1 mM PMSF, and protease inhibitor cocktail), followed by two steps of the dialysis (D1: 25 mM
Tris–HCl, 350 mM NaCl, 5 mM β-mercaptoethanol, 10% glycerol; D2: 25 mM Tris–HCl, 350 mM NaCl,
5 mM β-mercaptoethanol, 50% glycerol), yielding 2 μg of p66/p51 heterodimer per liter of cell culture.
The enzyme activity was 5500 U/mL.Fig. 3. PAGE of RT catalyzed pyrophosphorolysis inhibited by 2, 5, 10, 20, 50, and 100 μM of BPs 1, 12, 13 and 20, 50, 100, 200,
and 500 μM of BP 3.
Fig. 4. PAGE of RT catalyzed (A) pyrophosphorolysis inhibited by 2, 5, 20, 50, and 100 μM of BPs 12 and 13; (B) elongation
inhibited by 20, 50, 100, 200, and 500 μM of BPs 12 and 13.
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The [50-32P]-primer–template complexes (10 nM) were incubated with 0.5U HIV RT and 300 μM
PPi or 3 mM ATP in case of PP- and ATP-mediated phosphorolysis respectively in 10 μl of the reaction
buffer (50 mM Tris–HCl pH 8.0 or pH 7.5 for PP- and ATP-mediated phosphorolysis, respectively,
10 mM MgCl2, 60 mM KCl) in the presence of increasing concentrations of an bisphosphonate inhi-
bitors (Figs. 3 and 4A) at 37 °C for 30 min.2.2.4. Inhibition of RT polymerase activity
The [50-32P]-primer–template complexes (10 nM) were incubated with 0.5U HIV RT and 1 μM of
dATP, dTTP, dGTP, and dCTP in 10 μl of the reaction buffer (50 mM Tris–HCl pH 8.0, 10 mM MgCl2,
60 mM KCl) in the presence of increasing concentrations of an bisphosphonate inhibitors (Fig. 4B) at
37 °C for 30 min.2.2.5. Quantitative analysis of the RT inhibition
The reactions containing [50-32P]-primer–template complexes were stopped by 5 μl of stop solu-
tion, containing formamide, 10% of EDTA and 1 mg/ml each of bromphenol blue and xylene cyanol.
5 μl aliquot of the reaction was loaded onto 15% denaturing urea gel and subjected to electrophoresis
(2 h, 2400 V). Radioactive products were detected using Typhoon FLA 9500 biomolecular imager “GE
Healthcare” (UK). Spots on radioautograph images were interpreted using Opti-Quant software
(Packard Inc., USA) and IC50 were obtained graphically.Author contributions
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